Journal
MOLECULAR PHARMACEUTICS
Volume 8, Issue 6, Pages 2101-2141Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp200394t
Keywords
nanomedicine; nanopharmaceutical; nanoimaging agent; theranostic; regulation; cancer
Funding
- iMed.UL
- FCT
Ask authors/readers for more resources
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of nanomedicines began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available